{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:21:33Z","timestamp":1778253693968,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Hubei Province Scientific Research Project","award":["WJ2023M068"],"award-info":[{"award-number":["WJ2023M068"]}]},{"name":"Youth Interdisciplinary Special Fund of Zhongnan Hospital of Wuhan University","award":["ZNQNJC2022003"],"award-info":[{"award-number":["ZNQNJC2022003"]}]},{"name":"Knowledge Innovation Program of Wuhan-Shugung Project","award":["2023020201020510"],"award-info":[{"award-number":["2023020201020510"]}]},{"name":"Leading Discipline of Oncology Construction Project of Zhongnan Hospital of Wuhan University","award":["XKJS202005"],"award-info":[{"award-number":["XKJS202005"]}]},{"name":"Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University","award":["ZNJC202322"],"award-info":[{"award-number":["ZNJC202322"]}]},{"name":"Clinical Research Special Fund of Zhongnan Hospital of Wuhan University","award":["2025LCYJZX-MS009"],"award-info":[{"award-number":["2025LCYJZX-MS009"]}]},{"name":"Clinical Research Special Fund of Zhongnan Hospital of Wuhan University","award":["2025LCYJZX-ZD005"],"award-info":[{"award-number":["2025LCYJZX-ZD005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02801-y","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:20:44Z","timestamp":1748881244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Yanshuang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2801_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"key":"2801_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.acr.2021.05.002","volume":"152","author":"GR Bhat","year":"2021","unstructured":"Bhat GR, Hyole RG, Li J. Head and neck cancer: Current challenges and future perspectives. Adv Cancer Res. 2021;152:67\u2013102. https:\/\/doi.org\/10.1016\/bs.acr.2021.05.002.","journal-title":"Adv Cancer Res."},{"key":"2801_CR3","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937\u201344. https:\/\/doi.org\/10.1056\/NEJMoa032646.","journal-title":"N Engl J Med."},{"key":"2801_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","volume":"350","author":"J Bernier","year":"2004","unstructured":"Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945\u201352. https:\/\/doi.org\/10.1056\/NEJMoa032641.","journal-title":"N Engl J Med."},{"key":"2801_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med."},{"key":"2801_CR6","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/annonc\/mdq077","volume":"21","author":"R Mes\u00eda","year":"2010","unstructured":"Mes\u00eda R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21:1967\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdq077.","journal-title":"Ann Oncol"},{"key":"2801_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"2801_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(18)31999-8.","journal-title":"Lancet"},{"key":"2801_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"2801_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/jco.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790\u2013802. https:\/\/doi.org\/10.1200\/jco.21.02508.","journal-title":"J Clin Oncol"},{"key":"2801_CR11","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/s1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-509. https:\/\/doi.org\/10.1016\/s1470-2045(15)00007-8.","journal-title":"Lancet Oncol"},{"key":"2801_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/jco.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer. J Clin Oncol. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/jco.21.01308.","journal-title":"J Clin Oncol"},{"key":"2801_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23:209\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(21)00630-6.","journal-title":"Lancet Oncol"},{"key":"2801_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3309","author":"M Tachihara","year":"2023","unstructured":"Tachihara M, Tsujino K, Ishihara T, et al. Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: the DOLPHIN phase 2 nonrandomized controlled trial. JAMA Oncol. 2023. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3309.","journal-title":"JAMA Oncol"},{"key":"2801_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1292","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Feng M, Chen L, et al. Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer. Ann Oncol. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1292.","journal-title":"Ann Oncol"},{"key":"2801_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/jco.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride S, Sherman E, Tsai CJ, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021;39:30\u20137. https:\/\/doi.org\/10.1200\/jco.20.00290.","journal-title":"J Clin Oncol"},{"key":"2801_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:873\u201398. https:\/\/doi.org\/10.6004\/jnccn.2020.0031.","journal-title":"J Natl Compr Canc Netw"},{"key":"2801_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"2801_CR19","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749\u201368. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2996.","journal-title":"JAMA Oncol"},{"key":"2801_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22:450\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(20)30737-3.","journal-title":"Lancet Oncol."},{"key":"2801_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.029","author":"JP Machiels","year":"2022","unstructured":"Machiels JP, Tao Y, Burtness B, et al. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.029.","journal-title":"Ann Oncol"},{"key":"2801_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091324","author":"K Bal\u00e1zs","year":"2019","unstructured":"Bal\u00e1zs K, Kis E, Badie C, et al. Radiotherapy-Induced changes in the systemic immune and inflammation parameters of head and neck cancer patients. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091324.","journal-title":"Cancers"},{"key":"2801_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ygyno.2015.11.013","volume":"140","author":"ES Wu","year":"2016","unstructured":"Wu ES, Oduyebo T, Cobb LP, et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;140:76\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.013.","journal-title":"Gynecol Oncol."},{"key":"2801_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","volume":"105","author":"Y Cho","year":"2019","unstructured":"Cho Y, Park S, Byun HK, et al. Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2019;105:1065\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.047.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2801_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/jco.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36:1611\u20138. https:\/\/doi.org\/10.1200\/jco.2017.76.2229.","journal-title":"J Clin Oncol"},{"key":"2801_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.Cd-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M, et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12:108\u201333. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0003.","journal-title":"Cancer Discov"},{"key":"2801_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000537","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000537.","journal-title":"J Immunother Cancer"},{"key":"2801_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS\u207a\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014.","journal-title":"Cancer Cell"},{"key":"2801_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259\u201371. https:\/\/doi.org\/10.1084\/jem.20052494.","journal-title":"J Exp Med"},{"key":"2801_CR30","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83:1306\u201310. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.09.049.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2801_CR31","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","volume":"170","author":"M Chakraborty","year":"2003","unstructured":"Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338\u201347. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6338.","journal-title":"J Immunol"},{"key":"2801_CR32","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.Ccr-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 2018;24:5058\u201371. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3427.","journal-title":"Clin Cancer Res"},{"key":"2801_CR33","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.Can-09-2982","volume":"70","author":"T Takeshima","year":"2010","unstructured":"Takeshima T, Chamoto K, Wakita D, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70:2697\u2013706. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-2982.","journal-title":"Cancer Res"},{"key":"2801_CR34","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT, et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun. 2022;13:7015. https:\/\/doi.org\/10.1038\/s41467-022-34676-w.","journal-title":"Nat Commun"},{"key":"2801_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijrobp.2018.09.010","volume":"103","author":"LRG Pike","year":"2019","unstructured":"Pike LRG, Bang A, Mahal BA, et al. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys. 2019;103:142\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2801_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","volume":"108","author":"D Chen","year":"2020","unstructured":"Chen D, Verma V, Patel RR, et al. Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials. Int J Radiat Oncol Biol Phys. 2020;108:196\u2013203. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.032.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2801_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42\u201351. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.003.","journal-title":"Crit Rev Oncol Hematol."},{"key":"2801_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","volume":"1","author":"S Valpione","year":"2020","unstructured":"Valpione S, Galvani E, Tweedy J, et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020;1:210\u201321. https:\/\/doi.org\/10.1038\/s43018-019-0022-x.","journal-title":"Nat Cancer"},{"key":"2801_CR39","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1078-0432.Ccr-18-0793","volume":"25","author":"ML Gauci","year":"2019","unstructured":"Gauci ML, Lanoy E, Champiat S, et al. Long-term survival in patients responding to anti-PD-1\/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25:946\u201356. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0793.","journal-title":"Clin Cancer Res"},{"key":"2801_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13046-021-02224-x","volume":"41","author":"M Zhu","year":"2022","unstructured":"Zhu M, Zhang P, Yu S, et al. Targeting ZFP64\/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. J Exp Clin Cancer Res. 2022;41:14. https:\/\/doi.org\/10.1186\/s13046-021-02224-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"2801_CR41","doi-asserted-by":"publisher","first-page":"933646","DOI":"10.3389\/fonc.2022.933646","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, Tang Z, Guo X, et al. Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K\/AKT pathway through the Serpinc1 gene. Front Oncol. 2022;12:933646. https:\/\/doi.org\/10.3389\/fonc.2022.933646.","journal-title":"Front Oncol"},{"key":"2801_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdy507","volume":"30","author":"M Oliva","year":"2019","unstructured":"Oliva M, Spreafico A, Taberna M, et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2019;30:57\u201367. https:\/\/doi.org\/10.1093\/annonc\/mdy507.","journal-title":"Ann Oncol"},{"key":"2801_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"J Natl Cancer Inst"},{"key":"2801_CR44","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.Epi-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204\u201312. https:\/\/doi.org\/10.1158\/1055-9965.Epi-14-0146.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2801_CR45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/hed.24986","volume":"40","author":"Y Takenaka","year":"2018","unstructured":"Takenaka Y, Oya R, Kitamiura T, et al. Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: a meta-analysis. Head Neck. 2018;40:647\u201355. https:\/\/doi.org\/10.1002\/hed.24986.","journal-title":"Head Neck."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02801-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:20:45Z","timestamp":1748881245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02801-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Zhongnan Hospital of Wuhan University Research Ethics Committee (Approval No. 2021073) and performed in accordance with the principles of the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patients or their akin before data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"988"}}